• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两种恶唑烷酮类抗菌剂DuP 721和DuP 105的体外活性

In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

作者信息

Neu H C, Novelli A, Saha G, Chin N X

机构信息

Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

出版信息

Antimicrob Agents Chemother. 1988 Apr;32(4):580-3. doi: 10.1128/AAC.32.4.580.

DOI:10.1128/AAC.32.4.580
PMID:3377467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172224/
Abstract

The antibacterial activities of DuP 105 and DuP 721, new oxazolidinone antimicrobial agents, were compared with those of beta-lactams and glycopeptides. Ninety percent of Staphylococcus aureus and Staphylococcus epidermidis isolates, including methicillin-resistant isolates, were inhibited by 4 micrograms of DuP 105 and 1 microgram of DuP 721 per ml. DuP 721 inhibited hemolytic streptococcus groups A, B, C, F, and G at a concentration of less than or equal to 1 microgram/ml, and it inhibited viridans group streptococci at a concentration of 2 micrograms/ml. Both agents inhibited Listeria monocytogenes, Corynebacterium group JK species, anaerobic cocci, and Clostridium spp. including Clostridium difficile. They did not inhibit members of the family Enterobacteriaceae or Pseudomonas aeruginosa, but the MIC for 90% of Bacteroides fragilis isolates was 8 micrograms of DuP 721 per ml.

摘要

将新型恶唑烷酮类抗菌剂DuP 105和DuP 721的抗菌活性与β-内酰胺类和糖肽类抗菌剂进行了比较。每毫升含4微克DuP 105和1微克DuP 721可抑制90%的金黄色葡萄球菌和表皮葡萄球菌分离株,包括耐甲氧西林分离株。DuP 721在浓度小于或等于1微克/毫升时可抑制A、B、C、F和G组溶血性链球菌,在浓度为2微克/毫升时可抑制草绿色链球菌。这两种药物均可抑制单核细胞增生李斯特菌、JK组棒状杆菌属、厌氧球菌和梭菌属,包括艰难梭菌。它们不抑制肠杆菌科成员或铜绿假单胞菌,但90%脆弱拟杆菌分离株的最低抑菌浓度为每毫升8微克DuP 721。

相似文献

1
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.两种恶唑烷酮类抗菌剂DuP 721和DuP 105的体外活性
Antimicrob Agents Chemother. 1988 Apr;32(4):580-3. doi: 10.1128/AAC.32.4.580.
2
Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.
Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):256-60. doi: 10.1007/BF01965273.
3
In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones.新型合成恶唑烷酮DuP 105和DuP 721的体外微生物活性
J Antimicrob Chemother. 1988 Jun;21(6):711-20. doi: 10.1093/jac/21.6.711.
4
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
5
In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.新型恶唑烷酮类抗菌剂DuP 105和DuP 721的体外评价
Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150.
6
Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.恶唑烷酮类,一类新型合成抗菌剂:DuP 105和DuP 721的体外及体内活性
Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. doi: 10.1128/AAC.31.11.1791.
7
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.新型恶唑烷酮化合物DuP 105和DuP 721的活性及作用机制
J Antimicrob Chemother. 1988 Jun;21(6):721-30. doi: 10.1093/jac/21.6.721.
8
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.两种新型氟化恶唑烷酮U-100592和U-100766的体外抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
9
Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.
Diagn Microbiol Infect Dis. 1992 Sep-Oct;15(7):621-5. doi: 10.1016/0732-8893(90)90040-3.
10
In vitro activity of LY146032 (daptomycin), a new peptolide.新型缩酚肽LY146032(达托霉素)的体外活性
Eur J Clin Microbiol. 1987 Feb;6(1):84-90. doi: 10.1007/BF02097208.

引用本文的文献

1
The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy.五元杂环在治疗用抗菌药物分子结构中的作用。
Pharmaceutics. 2023 Oct 29;15(11):2554. doi: 10.3390/pharmaceutics15112554.
2
Stereoselective Synthesis of Oxazolidin-2-Ones via an Asymmetric Aldol/Curtius Reaction: Concise Total Synthesis of (-)-Cytoxazone.通过不对称醛醇缩合/Curtius 反应立体选择性合成恶唑烷-2-酮:(-)-细胞松弛素的简洁全合成。
Molecules. 2021 Jan 23;26(3):597. doi: 10.3390/molecules26030597.
3
Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.新型螺环哌嗪基恶唑烷酮类抗菌剂的合成及生物研究:利用螺环二烯衍生的酰基亚硝酰 Diels-Alder 反应。
Bioorg Med Chem. 2012 Jun 1;20(11):3422-8. doi: 10.1016/j.bmc.2012.04.026. Epub 2012 Apr 18.
4
A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?恶唑烷酮类药物的批判性综述:糖肽类和链阳菌素类的替代物还是替代品?
Can J Infect Dis. 2001 Nov;12(6):379-90. doi: 10.1155/2001/260651.
5
In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.新型恶唑烷酮类药物DA-7867对需氧革兰氏阳性菌的体外和体内活性
Antimicrob Agents Chemother. 2005 Jun;49(6):2498-500. doi: 10.1128/AAC.49.6.2498-2500.2005.
6
Clinical experience with linezolid in the treatment of resistant gram-positive infections.利奈唑胺治疗耐药革兰氏阳性菌感染的临床经验。
J Natl Med Assoc. 2001 Oct;93(10):386-91.
7
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.恶唑烷酮类化合物依哌唑胺(PNU - 100592)和利奈唑胺(PNU - 100766)与万古霉素相比,对金黄色葡萄球菌、凝固酶阴性葡萄球菌、粪肠球菌和屎肠球菌的体外比较活性及抗生素后效应。
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
8
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.恶唑烷酮类化合物U100592和U100766对金黄色葡萄球菌和表皮葡萄球菌的体外活性
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
9
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
10
In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.新型恶唑烷酮类抗菌剂U - 100592和U - 100766对实验性细菌感染的体内活性
Antimicrob Agents Chemother. 1996 Jun;40(6):1508-13. doi: 10.1128/AAC.40.6.1508.

本文引用的文献

1
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
2
The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.美国医院中耐甲氧西林金黄色葡萄球菌感染的出现。住院医生与患者转移循环的可能作用。
Ann Intern Med. 1982 Sep;97(3):297-308. doi: 10.7326/0003-4819-97-3-297.
3
Staphylococcus epidermidis infections.表皮葡萄球菌感染。
Ann Intern Med. 1983 Dec;99(6):834-9. doi: 10.7326/0003-4819-99-6-834.
4
Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.恶唑烷酮类,一类新型合成抗菌剂:DuP 105和DuP 721的体外及体内活性
Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. doi: 10.1128/AAC.31.11.1791.